Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MENASCORP is an equine-derived polyvalent antiserum developed by VinsBioproducts for the treatment of scorpion envenomation. It consists of purified F(ab')2 fragments of immunoglobulins obtained from the serum of healthy horses immunized against the venoms of *Leiurus quinquestriatus* (Deathstalker) and *Androctonus amoreuxi* (African Fat-tailed Scorpion). The mechanism of action involves passive immunization, where the polyclonal antibodies bind to and neutralize the circulating toxins in the scorpion venom, preventing them from reaching their physiological targets and facilitating their clearance. It is indicated for patients showing signs of systemic scorpion sting toxemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MENASCORP.